Literature DB >> 30719629

Rapid reconstitution packages (RRPs) for stable storage and delivery of glucagon.

Sebastian D'hers1, Agustín N Abad Vazquez2, Pablo Gurman2, Noel M Elman3.   

Abstract

Current emergency injectors of glucagon require manual reconstitution, which involves several steps that may lead to dosage errors. Rapid reconstitution packages (RRPs) are new devices, designed using computational fluid dynamics (CFD) to optimize fluid mixing, integrating physical properties of active pharmaceutical ingredients (APIs), excipients and diluents. RRPs improve drug stability for long-term storage and ease of delivery. Device prototypes were manufactured using advanced stereolithography apparatus (SLA) 3D printing technology. Reconstitution of glucagon with RRPs was evaluated by high-performance liquid chromatography (HPLC) and optical spectroscopy methods. Enzyme-linked immunosorbent assays were performed to test in vitro activity. Experimental results showed that RRPs effectively reconstituted glucagon even after exposure to 60 °C for a 24-h period. RRPs exhibited improved performance at maintaining drug stability compared to lyophilized glucagon stored in a standard glass vial under the same temperature conditions. RRPs represent a portable platform for rapid reconstitution of lyophilized drugs, compatible with standard syringes available in any clinical setting. The RRP provides an alternative to manual reconstitution process, especially designed for medical emergencies.

Entities:  

Keywords:  Ambulatory settings; Computational fluid dynamics (CFD); Diabetes; Drug delivery; Emergency medicine; Glucagon; Hypoglycemia; Microfluidics; Reconstitution; Stability

Mesh:

Substances:

Year:  2019        PMID: 30719629     DOI: 10.1007/s13346-019-00615-4

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  23 in total

Review 1.  Hierarchy of physiological responses to hypoglycemia: relevance to clinical hypoglycemia in type I (insulin dependent) diabetes mellitus.

Authors:  P E Cryer
Journal:  Horm Metab Res       Date:  1997-03       Impact factor: 2.936

2.  Reducing errors with injectable medications: unlabeled syringes are surprisingly common.

Authors:  Matthew Grissinger
Journal:  P T       Date:  2010-08

3.  Systematic evaluation of errors occurring during the preparation of intravenous medication.

Authors:  Christopher S Parshuram; Teresa To; Winnie Seto; Angela Trope; Gideon Koren; Andreas Laupacis
Journal:  CMAJ       Date:  2008-01-01       Impact factor: 8.262

Review 4.  Where errors occur in the preparation and administration of intravenous medicines: a systematic review and Bayesian analysis.

Authors:  Sarah E McDowell; Shahrul Mt-Isa; Deborah Ashby; R E Ferner
Journal:  Qual Saf Health Care       Date:  2010-01-11

Review 5.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

Review 6.  Intranasal glucagon: a promising approach for treatment of severe hypoglycemia.

Authors:  Antonio E Pontiroli
Journal:  J Diabetes Sci Technol       Date:  2014-11-10

Review 7.  Factors Associated with Needlestick Injuries in Health Care Occupations: A Systematic Review.

Authors:  Hossein Motaarefi; Hosein Mahmoudi; Eesa Mohammadi; Ali Hasanpour-Dehkordi
Journal:  J Clin Diagn Res       Date:  2016-08-01

Review 8.  Hypoglycemia in diabetes.

Authors:  Philip E Cryer; Stephen N Davis; Harry Shamoon
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

9.  A novel nasal powder formulation of glucagon: toxicology studies in animal models.

Authors:  Frederick E Reno; Patrick Normand; Kevin McInally; Sherwin Silo; Patricia Stotland; Myriam Triest; Dolores Carballo; Claude Piché
Journal:  BMC Pharmacol Toxicol       Date:  2015-10-26       Impact factor: 2.483

10.  Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.

Authors:  Jennifer L Sherr; Katrina J Ruedy; Nicole C Foster; Claude A Piché; Hélène Dulude; Michael R Rickels; William V Tamborlane; Kathleen E Bethin; Linda A DiMeglio; Larry A Fox; R Paul Wadwa; Desmond A Schatz; Brandon M Nathan; Santica M Marcovina; Emmanouil Rampakakis; Linyan Meng; Roy W Beck
Journal:  Diabetes Care       Date:  2016-02-16       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.